Skip to content
Home/Companies/MedTech/Ivantis

Ivantis

MedTech·US·Exited 2022·Held 5yr
Entry
2017
Hold
5yr
Exit
2022

Who owns Ivantis?

Ivantis is an American MedTech company, now owned by Alcon, which acquired it in 2022 from Merieux Equity Partners.

Hand-verified · updated 2026-09-30

Open JSON · CC-BY
Merieux Equity Partners
Investor
Merieux Equity Partners
Mérieux Innovation 1 · 2014 · VC

Key facts

HQUS
SectorMedTech
StatusAcquired
Exit Type
Trade Sale
Buyer
Alcon
Exit Year
2022

More from Mérieux Innovation 1

Other portfolio companies in the same fund.

Broken String Biosciences
Broken String Biosciences
Active
BiotechUK· 2023
InnoSyn
InnoSyn
Active
PharmaNetherlands· 2023
LabQuality
LabQuality
Exited 2025
HealthcareFrance· 2023
to Aurevia
Cairdac
Cairdac
Active
MedTechFrance· 2022
Mablink Bioscience
Exited 2023
BiotechFrance· 2022
to Eli Lilly and Company
SeqOne Genomics
SeqOne Genomics
Active
BiotechFrance· 2022

More PE-backed in MedTech

Comparable medtech deals from other GPs.

Acufocus, Inc.
Exited 2023
The Carlyle GroupUS
to Bausch + Lomb
Adicon Holdings Limited
Active
The Carlyle GroupUS
Aesynt
Exited 2016
Francisco PartnersUS
to Omnicell
Alere Medical, Inc.
Active
TA AssociatesUS
Alma Lasers, Ltd.
Alma Lasers, Ltd.
Active
TA AssociatesIsrael
Amedes Group
Active
General AtlanticGermany

Questions

Who owns Ivantis?

Ivantis is now owned by Alcon, which acquired it in 2022 from Merieux Equity Partners.

When did Alcon acquire Ivantis?

Alcon acquired Ivantis in 2022, buying from Merieux Equity Partners.

Who did Ivantis sell to?

Merieux Equity Partners sold Ivantis to Alcon in 2022 (Trade Sale).

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue